RxDoctor Payments Data

Adrian Renaldi, DO

Internal Medicine · Rio Rancho, NMNPI 1275099699

Payments from drug & device makers

$686in general payments, 2019–2025

Across 31 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$118
  • Insulet Corporation$89
  • Exact Sciences$73
  • Lilly USA, LLC$66
  • Viatris Specialty LLC$53
  • Antares Pharma, Inc.$47
  • plus $239 from 8 others

What the payments were for

  • Food & beverage$686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$686 in reported general payments places this provider in the 80th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$1,022
Medicare patients
70
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide53$66,490
OzempicSemaglutide46$65,871
EliquisApixaban44$46,765
XareltoRivaroxaban26$37,278
JardianceEmpagliflozin31$34,628
FarxigaDapagliflozin Propanediol39$32,161
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,830
Spiriva HandihalerTiotropium Bromide21$12,514
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl48$8,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$8,301
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,442
Rosuvastatin Calcium219$5,186
Humalog Kwikpen U-100Insulin Lispro20$4,153
Ventolin HfaAlbuterol Sulfate37$3,008
Albuterol Sulfate HfaAlbuterol Sulfate115$2,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$66$66,49053 claims
PfizerEliquis$36$46,76544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Rio Rancho

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →